NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives
Journal of Clinical Medicine · 06.02.2025 · 14 (3) · 1025
DOI: 10.3390/jcm14031025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.02.2025. Verfasst von Kareem Tahayneh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Quds University, East Jerusalem 20002, Palestine. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung carcinoma (NSCLC) comprises the majority of lung cancer cases, characterized by a complex interplay of genetic alterations, environmental factors, and molecular pathways contributing to its pathogenesis. This article highlights the multifaceted pathogenesis of NSCLC and discusses screening and integrated strategies for current treatment options. NSCLC is an evolving field with various aspects including the underlying molecular alterations, oncogenic driver mutations, and immune microenvironment interactions that influence tumor progression and response to therapy. Surgical treatment remains the most applicable curative option, especially in the early stages of the disease, adjuvant chemotherapy may add benefits to previously resected patients. Combined Radio-chemotherapy can also be used for palliative purposes. There are various future perspectives and advancing horizons in NSCLC management, encompassing novel therapeutic modalities and their applications, such as CAR-T cell therapy, antibody-drug conjugates, and gene therapies. On the other hand, it’s crucial to highlight the efficacy of innovative modalities of Immunotherapy and immune checkpoint inhibitors that are nowadays widely used in treatment of NSCLC. Moreover, the latest advancements in molecular profiling techniques and the development of targeted therapies designed for specific molecular alterations in NSCLC play a significant role in its treatment. In conclusion, personalized approaches are a cornerstone of successful treatment, and they are based on a patient’s unique molecular profile, tumor characteristics, and host factors. Entitling the concept of individualized treatment strategies requires proper patient selection, taking into consideration mechanisms of resistance, and investigating potential combination therapies, to achieve the optimal impact on long-term survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Al-Quds University, East Jerusalem 20002, Palestine.
- Department of General Surgery, Faculty of Medicine, Al-Quds University, East Jerusalem 20002, Palestine.
- Department of Thoracic Surgery, The Edith Wolfson Medical Center, Holon 58100, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Zitieren
APA
Tahayneh, K., Idkedek, M., & Abu Akar, F. (2025). NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives. Journal of Clinical Medicine, 14(3), 1025. https://doi.org/10.3390/jcm14031025
Vancouver
Tahayneh K, Idkedek M, Abu Akar F. NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives. Journal of Clinical Medicine. 2025;14(3):1025. doi:10.3390/jcm14031025
BibTeX
@article{Tahayneh2025,
author = {Tahayneh, Kareem and Idkedek, Mayar and Abu Akar, Firas},
title = {NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {3},
pages = {1025},
doi = {10.3390/jcm14031025}
}
EUVIMED